BioLineRx Ltd. Files Form 6-K
Ticker: BLRX · Form: 6-K · Filed: Nov 5, 2024 · CIK: 1498403
| Field | Detail |
|---|---|
| Company | Biolinerx LTD. (BLRX) |
| Form Type | 6-K |
| Filed Date | Nov 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
BioLineRx dropped a 6-K on Nov 5th, likely with news. Check the exhibit for deets.
AI Summary
BioLineRx Ltd. filed a Form 6-K on November 5, 2024, to report the issuance of a press release. The filing itself does not contain the details of the press release, only that it was issued on that date. The company is incorporated in Israel and its principal executive offices are located in Modi'in.
Why It Matters
This filing indicates that BioLineRx Ltd. has released new information to the public, which could contain material updates relevant to investors.
Risk Assessment
Risk Level: low — This filing is a routine report of a press release and does not contain specific financial or operational disclosures that would inherently increase risk.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- November 5, 2024 (date) — Filing date and press release issuance date
- 001-35223 (other) — Commission file number
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report the issuance of a press release by BioLineRx Ltd. on November 5, 2024.
When was this Form 6-K filed?
This Form 6-K was filed on November 5, 2024.
What is the company's commission file number?
The company's commission file number is 001-35223.
Where are BioLineRx Ltd.'s principal executive offices located?
BioLineRx Ltd.'s principal executive offices are located at 2 HaMa'ayan Street, Modi'in 7177871, Israel.
Does BioLineRx Ltd. file annual reports under Form 20-F or Form 40-F?
BioLineRx Ltd. files annual reports under Form 20-F, as indicated by the checkmark next to 'Form 20-F'.
Filing Stats: 150 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-11-05 09:06:03
Filing Documents
- zk2432221.htm (6-K) — 9KB
- exhibit_1.htm (EX-99.1) — 22KB
- image00001.jpg (GRAPHIC) — 402KB
- 0001178913-24-003475.txt ( ) — 585KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On November 5, 2024, the Registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: November 5, 2024